Incyte
Incyte Corporation, a leading biopharmaceutical company headquartered in the United States, has been at the forefront of innovative cancer therapies since its founding in 1991. With a strong focus on oncology, Incyte develops and commercialises novel treatments that address unmet medical needs, particularly in the fields of haematology and solid tumours. The company is renowned for its flagship product, Jakafi (ruxolitinib), which was the first FDA-approved JAK1/JAK2 inhibitor, offering unique therapeutic options for patients with myelofibrosis and polycythaemia vera. Incyte's commitment to research and development has positioned it as a key player in the biopharmaceutical industry, with a robust pipeline of investigational therapies aimed at improving patient outcomes. With a global presence, Incyte continues to make significant strides in advancing cancer care and enhancing the quality of life for patients worldwide.
DitchCarbon Score
How does Incyte's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Incyte's score of 29 is higher than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Incyte's reported carbon emissions
Incyte Corporation, headquartered in the US, reported its carbon emissions for 2023, totalling approximately 12,924,000 kg CO2e across all scopes. This includes 9,351,000 kg CO2e from Scope 1, 865,000 kg CO2e from Scope 2 (market-based), and 12,924,000 kg CO2e from Scope 3 emissions. The company has shown a commitment to reducing its carbon footprint, although no specific reduction targets or initiatives have been disclosed. Incyte's emissions data for previous years indicates a trend of increasing emissions, with 2022 figures at about 10,917,000 kg CO2e and 2021 at approximately 4,224,000 kg CO2e for Scope 3. The company has not inherited emissions data from any parent organisation, and all reported figures are directly from Incyte Corporation. The emissions intensity metrics for Scope 1 and Scope 2 are reported as 2.8e-06 kg CO2e per $1M revenue, 0.0108 kg CO2e per 1,000 square feet, and 4.0 kg CO2e per employee for 2023. These metrics provide insight into the company's operational efficiency in relation to its carbon emissions. In summary, while Incyte has made strides in transparency regarding its emissions, it currently lacks defined reduction targets or specific climate pledges, positioning it within an industry context that increasingly prioritises sustainability and carbon neutrality.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 4,775,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 7,451,000 | 0,000,000 | 000,000 | 0,000,000 | 000,000 |
| Scope 3 | 7,165,000 | 0,000,000 | 0,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Incyte is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
